MedTrace Logo

Metyrapone as Additive Treatment in Major Depression

NCT00125554 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2005-08-12

No results posted yet for this study

Summary

The purpose of this study is to test whether metyrapone is an effective and safe augmenting agent in the treatment of major depression.

Conditions

Interventions

DRUG

Metyrapone

Sponsors & Collaborators

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Principal Investigators

  • Holger Jahn, MD · University Hospital Hamburg-Eppendorf, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-05-31
Completion
2001-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00125554 on ClinicalTrials.gov